New therapeutic option With N-acetylcysteine for primary sclerosing cholangitis: Two case reports
| Autor: | Burhan Özdil, Hikmet Akkiz, Arif Coşar, Can Kece, Macit Sandikci |
|---|---|
| Přispěvatelé: | Çukurova Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Cholagogues and Choleretics Cholangitis Sclerosing Gastroenterology Primary sclerosing cholangitis Acetylcysteine Young Adult Cholestasis Fibrosis Internal medicine medicine Humans cholestatic hepatic disease Pharmacology (medical) Pharmacology Mucolytic Agent business.industry primary sclerosing cholangitis General Medicine Free Radical Scavengers medicine.disease Ursodeoxycholic acid Tacrolimus N-acetylcysteine ursodeoxycholic acid Liver Etiology Female business medicine.drug |
| Popis: | PubMedID: 20019586 Primary sclerosing cholangitis is a progressive, cholestatic hepatic disease of unknown etiology. It is characterized by progressive inflammation, destruction, and fibrosis of the intrahepatic and extrahepatic bile ducts. Several medical therapies have been tried such as penicilamin, colchicine, methatraxate, cyclosporine, tacrolimus, and ursodeoxycholic acid. Treatment with mucolytic agents in excessively high viscosity conditions appears to have an important role. N-acetylcysteine (NAC), as a mucolytic agent, may fascilitate the drainage in partial obstructions by decreasing the mucous viscosity. We suggest that NAC and ursodeoxycholic acid have markedly positive effects on the clinical course of cholangitis and cholestasis when used together by affecting bile viscosity. Here, we present two cases treated with NAC. NAC capsul therapies at 800 mg/day were administered to two patients with primary sclerosing cholangitis. Clinical and laboratory parameters of patients saw significant improvement. © 2011 Lippincott Williams & Wilkins. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|